- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02142114
Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles
The purpose of this study is to determine if a smaller needle size reduces discomfort suffered by patients both during and following intravitreal injections. It is the investigators belief that using a smaller size needle will help patients to be less fearful of intravitreal injections and more amenable to treatment. This study will also evaluate the effect of needle size on post injection intraocular pressure, to see if smaller needles may reduce wound leak and increase the intraocular pressure following injection.
The investigators hypothesize that subject eyes injected with the smaller size needle will result in greater patient comfort both during and after their injection as compared to the eye injected with the larger needle. The investigators objective is to reduce any discomfort felt by patients who receive intravitreal injections. The investigators also hypothesize that the smaller needle will result in higher post injection pressures, and another objective is to determine if this can affect patient comfort and increase the risk of glaucomatous optic nerve damage.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Gabriel M Gordon, Ph.D.
- Phone Number: 805-895-6666
- Email: gabrielmgordon@gmail.com
Study Locations
-
-
Florida
-
Fort Myers, Florida, United States, 33907
- Recruiting
- Retina Health Center
-
Contact:
- Gabriel M Gordon, Ph.D.
- Phone Number: 805-895-6666
- Email: gabrielmgordon@gmail.com
-
Principal Investigator:
- Alexander M Eaton, M.D.
-
Sub-Investigator:
- Hussein Wafapoor, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age > 18 years
- Subject's normal therapeutic regimen calls for them to receive two sessions of bilateral injections of the same volume of ranibizumab within the next year.
- Disease related considerations: None.
- Other considerations: Subjects who must be able to report pain scores during and up to 48 hours following an intravitreal injection. Also, subjects must consent to at least 5 intraocular pressure checks per eye for each injection procedure.
Exclusion Criteria:
- Pregnancy (positive pregnancy test) or lactation
- Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an intrauterine device, or contraceptive hormone implant or patch.
- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
- special classes of subjects (vulnerable subjects), such as fetuses, pregnant women, children, institutionalized mentally disabled, or others, especially those whose ability to give voluntary informed consent may be in question.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Eye injection by 30 gauge needle
Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle.
Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen.
On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly.
The other eye will be injected with the other needle size (may be that day or within 1 week of the 1st injection).
When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
|
Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle.
Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen.
On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly.
The other eye will be injected with the other needle size.
When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
|
Active Comparator: Eye injection by 32 gauge needle
|
Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle.
Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen.
On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly.
The other eye will be injected with the other needle size.
When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain assessment.
Time Frame: Immediately following an injection and follow-up within 48 hours of the injection.
|
Following each session of injections, the patient will be asked to fill out a short questionnaire regarding the comfort levels of the two needle sizes.
Also, all subjects will be followed up by phone within 48 hours to assess any post-injection pain.
|
Immediately following an injection and follow-up within 48 hours of the injection.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraocular pressure assessment
Time Frame: 1 minute prior, as well as 1, 3, 10, and 30 minutes post-injection
|
As a secondary end point, pre and post injection intraocular pressure measurements will also be taken prior to each intravitreal injection by tonopen, as well as at 1-, 3-, 10-, and 30- minutes post-Intravitreal injection.
|
1 minute prior, as well as 1, 3, 10, and 30 minutes post-injection
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alexander M Eaton, M.D., Retina Health Center
- Study Director: Gabriel M Gordon, Ph.D., Retina Health Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ML29182
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on Eye injection by 30 or 32 gauge needle
-
Northwestern UniversityCompleted